콘딜로마 치료에서의 현재의 치료 접근법은 주로 눈에 보이는 병변과 사마귀의 제거에 초점을 맞추었습니다. 그러나 기존 치료가 질병을 근절하거나 재발률을 크게 줄이는 장기적인 효능을 뒷받침하는 증거는 제한되어 있습니다. 또한, 현재 사용되는 치료법은 다양하며 비용, 부작용 프로파일, 투여 일정, 치료 기간 및 전반적인 효능에 따라 크게 다를 수 있습니다. 현재, 컨디로마의 치료에는 국소 치료(ALDARA, ZYCLARA(imiquimod), CONDYLOX(podofilox 또는 podofyllin) 등) 및 VEREGEN(시네카테킨스) 및 전신 치료(Alferon N 등)가 포함됩니다. 콘딜로마 시장의 역학은 질병에 대한 인식 증가와 세계 백신 개발에 의해 향후 몇 년 동안 변화할 것으로 예측됩니다. 콘딜로마 치료의 개발에 종사하는 중요한 존재로는 Verrica Pharmaceuticals의 YCANTH(VP-102) 등이 있습니다.
본 보고서에서는 컨디로마의 주요 7개 시장(미국, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본)에 대한 조사 분석을 실시하고, 각국 시장 규모와 예측, 각 치료법 시장 점유율, 현재의 치료법, 암멧 필요 등의 정보를 제공합니다.
DelveInsight's "Condyloma - Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of condyloma epidemiology, market, and clinical development in condyloma. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the condyloma market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The condyloma market report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted condyloma market size from 2020 to 2034 in 7MM. The report also covers current condyloma treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.
Condyloma Overview
Condyloma refers to a wart-like growth on the genitals or around the anus. It is caused by certain types of human papillomavirus (HPV), particularly types 6 and 11. It is a sexually transmitted infection that spreads through sexual or skin-to-skin contact with an infected person. Further, several factors such as having multiple sexual partners, early sexual activity, unprotected sex, weekend immunity, and existing sexually transmitted infections (STIs) can increase the risk of transmitting genital HPV. Additionally, in children it may also be transmitted through nonsexual ways, such as from an infected mother to her infant or through direct manual contact.
The common symptoms of condyloma include soft lumps in or around the anus; light brown, yellow, pink, or flesh-colored lumps that may cluster together; bleeding; itching or discomfort in the genital area; and increased vaginal discharge. While these growths are generally benign, some strains of HPV are linked to more serious conditions, including cervical cancer in women.
Condyloma Diagnosis
The diagnosis of condyloma is usually made by visual inspection but can be confirmed by biopsy, which is indicated if lesions are atypical (e.g., pigmented, indurated, and affixed to underlying tissue, bleeding, or ulcerated lesions). It may begin with a physical examination of all potentially affected mucocutaneous and anogenital areas (including a pelvic exam for women). Colposcopy is often used as a diagnostic tool, involving the application of a mild acetic acid solution to the genital area, which causes warts to temporarily turn white, making them easier to detect under a lighted magnifying instrument. In women, a Pap test may be performed to detect cervical cell abnormalities, and if abnormal results are found, an HPV test can identify high-risk viral strains. In certain cases, a cervical biopsy may be taken to check for precancerous or cancerous changes, with biopsy generally reserved for atypical or suspicious lesions.
Condyloma Treatment
The treatment of condyloma involves multiple approaches depending on the number, size, and location of lesions, as well as patient preferences. Topical medications such as imiquimod (ALDARA, ZYCLARA), podophyllin and podofilox (CONDYLOX), sinecatechins (VEREGEN), and systemic therapies like Alferon N are commonly used treatment options. For extensive, resistant, or recurrent lesions, procedure interventions including cryotherapy with liquid nitrogen, electrocautery, carbon dioxide laser ablation, and surgical excision can be used. In refractory cases, interferon therapy may be considered.
The primary aim of treatment includes the removal of visible lesions and alleviation of associated symptoms. However, it does not cure the underlying HPV infection, so warts may recur. Regular follow-up may be necessary to monitor and manage recurrences effectively. Patients are advised to avoid over-the-counter wart treatments meant for non-genital warts, as these are not suitable for the genital area.
The condyloma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as incident cases of condyloma, gender-specific incident cases of condyloma, age-specific incident cases of condyloma, and anatomical location-specific incident cases of condylomain the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.
The drug chapter segment of condyloma report encloses a detailed analysis of condyloma-marketed drugs and emerging pipeline drugs. It also deep dives into condyloma's pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.
Marketed Drugs
VEREGEN: MediGene
VEREGEN, a topical treatment for external genital warts, contains a concentrate of catechins with a complex, defined composition extracted from green tea leaves. MediGene acquired the basic rights to the active ingredient in VEREGEN from Epitome Pharmaceuticals and was solely responsible for the drug's successful preclinical and clinical development, as well as the approval process. It was first approved by the US FDA in October 2006 for the treatment of external genital warts. In Europe, it received its initial approval in Germany in 2009, which then served as the reference for the mutual recognition procedure (MRP) in other European countries. By early 2015, marketing authorization had been secured in multiple markets, including the UK and Italy, along with several other European regions.
Emerging Drugs
YCANTH (VP-102): Verrica Pharmaceuticals
YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration. In November 2024, the company announced the results from its Phase II trial of VP-102, demonstrating that VP-102 significantly outperforms standard treatments for condyloma. As per the company's pipeline, there are currently no plans to initiate a Phase III trial.
The current therapeutic approaches for the treatment of condyloma are primarily focused on the removal of visible lesions or warts. However, there is limited evidence to support the long-term efficacy of existing treatments in eradicating the condition or significantly reducing recurrence rates. Further, a wide range of therapies are presently in use, which are highly variable and can differ dramatically with respect to cost, side-effect profiles, dosing schedules, duration of treatment, and overall effectiveness. Currently, the treatment of condyloma includes topical treatment (such as ALDARA, ZYCLARA (imiquimod), CONDYLOX (podofilox or podophyllin)), and VEREGEN (sinecatechins), and systemic treatment (such as Alferon N). The dynamics of condyloma market is anticipated to change in the coming years owing to the rising awareness of the disease, and the development of vaccines across the world. The major key players involved in the development for the treatment of condyloma are YCANTH (VP-102) by Verrica Pharmaceuticals, and others.
Condyloma Drug Uptake
This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025-2034, which depends on the competitive landscape, safety, and efficacy data, along with the order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.
Condyloma Pipeline Development Activities
The report provides insights into different therapeutic candidates in the marketed and emerging stages. It also analyses key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for condyloma therapies.
KOL Views
To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Professors, and others.
DelveInsight's analysts connected with 15+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as University Medical Center Hamburg-Eppendorf, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or condyloma market trends.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
Reimbursement may be referred to as the negotiation of a price between a manufacturer and a payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs) and third-party organizations that provide services and educational programs to aid patients are also present.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
10.. Patient Journey
Lit to be continued in the report...